Forest Laboratories encounters setbacks on 2 drugs

03/8/2009 | Forbes

Forest Laboratories said it is postponing the launch of fibromyalgia treatment Savella until midyear, when the FDA is expected to respond to changes that Forest and partner Cypress Biosciences made to the drug's formula. Forest also announced that it will delay its application for FDA approval of aclidinium bromide, its candidate for chronic obstructive pulmonary disease, until additional clinical trials have been conducted.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR